CP

Caligan Partners Portfolio holdings

AUM $515M
This Quarter Return
+9.22%
1 Year Return
+70.09%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$395M
AUM Growth
+$395M
Cap. Flow
+$46.2M
Cap. Flow %
11.69%
Top 10 Hldgs %
94.3%
Holding
16
New
4
Increased
5
Reduced
1
Closed
2

Top Buys

1
SAGE
Sage Therapeutics
SAGE
$16.6M
2
MRUS icon
Merus
MRUS
$10.7M
3
EOLS icon
Evolus
EOLS
$5.51M
4
ABVX
Abivax
ABVX
$5.51M
5
VRCA icon
Verrica Pharmaceuticals
VRCA
$5.2M

Top Sells

1
IMAB
I-MAB
IMAB
$4.34M
2
OTLK icon
Outlook Therapeutics
OTLK
$1.7M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
$791K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$2.38B
$116M 29.26%
8,118,592
– –
VRNA
2
Verona Pharma
VRNA
$9.16B
$66.7M 16.9%
1,436,878
– –
EXEL icon
3
Exelixis
EXEL
$10.1B
$50.8M 12.87%
1,525,730
– –
EOLS icon
4
Evolus
EOLS
$494M
$29.7M 7.53%
2,692,388
+498,900
+23% +$5.51M
ANIK icon
5
Anika Therapeutics
ANIK
$135M
$23.6M 5.98%
1,435,130
– –
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$1.74B
$22.5M 5.71%
2,995,932
+412,347
+16% +$3.1M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.19B
$20.6M 5.21%
626,280
+46,563
+8% +$1.53M
SAGE
8
DELISTED
Sage Therapeutics
SAGE
$16.6M 4.2%
+3,052,538
New +$16.6M
YMAB icon
9
Y-mAbs Therapeutics
YMAB
$388M
$13.8M 3.51%
1,767,982
+572,729
+48% +$4.48M
MLYS icon
10
Mineralys Therapeutics
MLYS
$1.03B
$12.4M 3.15%
1,011,155
+30,000
+3% +$369K
MRUS icon
11
Merus
MRUS
$4.98B
$10.7M 2.72%
+255,000
New +$10.7M
ABVX
12
Abivax
ABVX
$6.12B
$5.51M 1.39%
+752,167
New +$5.51M
VRCA icon
13
Verrica Pharmaceuticals
VRCA
$52.8M
$5.2M 1.32%
+7,429,687
New +$5.2M
ENTA icon
14
Enanta Pharmaceuticals
ENTA
$180M
$1.06M 0.27%
184,826
-137,627
-43% -$791K
IMAB
15
I-MAB
IMAB
$340M
– –
-3,499,330
Closed -$4.34M
OTLK icon
16
Outlook Therapeutics
OTLK
$37.8M
– –
-318,699
Closed -$1.7M